Quick Facts

• Primary Use: Management of blood glucose in adults with type 2 diabetes mellitus.
• Goal: To improve glycemic control when diet and exercise alone do not provide sufficient effect.

---

Endial Met is a combination therapy utilized in the comprehensive management of type 2 diabetes mellitus. This medication is indicated for use as an adjunct to proper diet and exercise to improve glycemic control in adult patients.

Through its combination of active agents, Endial Met assists in the body's management of blood sugar levels. One component works to help the body use its existing insulin more efficiently while reducing the amount of glucose produced by the liver. The second component is intended to stimulate the timely release of insulin from the pancreas, contributing to better overall glucose homeostasis.

Clinical data demonstrates that Endial Met supports patients in achieving and maintaining stable blood glucose levels over time. The therapeutic applications of the components of this drug are intended for the management of type 2 diabetes.

The official regulatory profile for Endial Met strictly defines who is eligible to use the medicine. It is indicated only for adult patients with Type 2 Diabetes Mellitus whose blood sugar is inadequately controlled by other treatments.

---

The medicine is contraindicated and must not be used by patients with:

• Severe renal failure (GFR below 30 mL/min/1.73 m^2), severe hepatic disorders, or acute conditions that may compromise kidney function.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Known hypersensitivity to glimepiride, metformin, other sulfonylureas, or sulfonamides.
• Women who are pregnant or breast-feeding.

---

Use is not established for pediatric patients. For older adults (≥ 65 years), the drug should be used with caution, and renal function must be assessed frequently. Furthermore, the medicine requires temporary suspension before or during certain surgical procedures or medical imaging that involves intravascular iodinated contrast agents. The profile strictly limits use based on the patient’s documented condition and compliance with all labeled restrictions.

The official interaction profile for Endial Met, combining Glimepiride and Metformin, is documented across several regulatory classifications.

Interaction Classifications

Classification	Examples of Interacting Agent Types
Pharmacodynamic Reinforcement	Insulin, Other Sulfonylureas, Oral Miconazole
Exposure and Metabolic Alteration	CYP2C9 Inhibitors/Inducers, Colesevelam
Clearance Reduction Risk	Carbonic Anhydrase Inhibitors, Renal Transporter Inhibitors

Official Interaction Statements

The co-administration of Iodinated Contrast Materials for imaging procedures is formally restricted, requiring Endial Met (Metformin component) to be temporarily discontinued at the time of or prior to the procedure, and for 48 hours afterward, due to the documented risk of lactic acidosis.

Regarding absorption, the Glimepiride component's exposure (AUC and Cmax) is documented to be reduced by Colesevelam, mandating that Endial Met must be administered at least 4 hours prior to Colesevelam.

Excessive alcohol intake is officially documented to potentiate the Metformin effect on lactate metabolism, significantly increasing the risk of lactic acidosis.

Substances that inhibit renal transporters, such as Cimetidine, Ranolazine, and Vandetanib, may increase Metformin plasma concentrations by reducing its clearance. The interaction of Glimepiride is based on CYP2C9 enzyme inhibition or induction, which officially alters Glimepiride exposure. In elderly patients and those with renal impairment, the risk of interactions leading to hypoglycemia and lactic acidosis is officially noted as heightened due to age-related decline in renal function.

This structure defines the product’s official interaction profile across metabolic, clearance, and timing-based constraints, as specified in regulatory documents.

How Endial Met Works: Mechanism of Action

Endial Met exerts its action via two distinct, complementary pharmacodynamic domains that modulate systemic glucose homeostasis.

Controlling Hepatic Glucose Production

One component of the drug acts primarily within liver cells (hepatocytes) by modulating mitochondrial function, which results in the allosteric activation of the cellular energy sensor, AMP-activated protein kinase (AMPK). This molecular cascade suppresses the metabolic pathway responsible for the liver's endogenous sugar synthesis (gluconeogenesis). The subsequent physiological effect is a reduction in the overall release of sugar into the bloodstream, which is a key mechanistic factor in lowering basal circulating sugar.

---

Augmenting Incretin Hormone Signaling

The second component achieves its effect by reversibly inhibiting the Dipeptidyl Peptidase-4 (DPP-4) enzyme. This enzymatic inhibition prevents the rapid deactivation of the gastrointestinal hormones GLP-1 and GIP (incretins). The preservation of active incretins results in an augmented, glucose-dependent release of insulin from the pancreas. This pathway adjustment facilitates increased uptake and removal of sugar from the circulation, particularly in the postprandial state.

Administration Scope

Parameter	Instruction
Route of administration	Strictly oral administration as a Fixed-Dose Combination (FDC) tablet.
Dosing schedule	Dosing is individualized to the patient’s metabolic response, beginning at the lowest effective dose. The maximum allowed daily dose is Glimepiride 8 mg and Metformin 2000 mg. Dose adjustment must be gradual, usually occurring in stepwise increments over intervals of one to two weeks.
Timing in relation to meals (if applicable)	The tablet must be taken shortly before or with a meal, commonly with the main meal of the day (such as breakfast) for once-daily regimens.
Preparation requirements (if applicable)	Tablets, especially prolonged-release forms, must not be crushed or chewed and should be swallowed whole with liquid.
Age-group administration rules	Use in older adults requires caution due to the likelihood of age-related decline in renal function. Safety and effectiveness have not been established in pediatric patients.
Missed-dose rules	A forgotten dose must never be corrected by subsequently taking a larger dose at the next scheduled time.
Special procedural conditions	Dosage is dependent on renal function. Metformin is contraindicated if the estimated Glomerular Filtration Rate (eGFR) is below 30 mL/min/1.73 m^2.

---

Instruction Classifications (High-Level)

Parameter	Classification
Administration method type	Oral
Frequency pattern	Daily
Basis of use	Clinical and pharmacological parameters
Use-context constraints	Food-dependent timing and eGFR-dependent dosing.

---

Resulting Procedural Structure

Step sequence:

• Initiate therapy at the lowest effective dose.
• Consume the tablet with or immediately before a main meal once or twice daily.
• Monitor metabolic status and adjust the dose gradually in small increments.
• If a dose is missed, skip the missed dose and resume the regular schedule.
• Dose must be reduced or discontinued if metabolic control improves or if renal function declines below specific eGFR thresholds.

Connection to the overall use protocol (2–4 sentences): This protocol establishes the administrative parameters for Endial Met, defining the dose, timing, and long-term adjustment strategy. These instructions govern how the medication is utilized, emphasizing an initial low dose, meal-dependent intake, and the role of gradual, individualized dose management over the course of the therapy.

Endial Met: Recent Clinical Evidence

Core Research and Study Types

Research for the fixed-dose combination (FDC) of Glimepiride and Metformin (Endial Met) was studied in research exploring blood sugar levels in adults whose control was not meeting pre-defined targets using a single antidiabetic medicine. Randomized Controlled Trials (RCTs) represent the primary body of evidence, comparing the FDC against monotherapy or other combination regimens to monitor outcomes related to systemic imbalance. Research examined glycemic biomarker shifts, primarily monitoring Glycated Hemoglobin (HbA1c)—a standard measurement used to track average blood sugar levels.

Data show patterns related to these measurements, with studies reporting how outcomes evolved in observed populations. Furthermore, Real-World Evidence (RWE) describes studies that reflect treatment patterns outside of controlled trials, providing context but not individual predictions. Studies also monitored other outcomes related to systemic imbalance, such as tracking changes in body weight and lipid profile (cholesterol and triglycerides).

Evidence in Specific Patient Groups

The FDC was studied for use in various patient populations, including those with HbA1c levels not meeting pre-defined targets despite previous efforts. Subgroups defined by co-existing conditions, known as comorbidities, were observed in some studies, such as patients with high blood pressure or high cholesterol. However, results apply only to the populations studied, and data for certain groups remain insufficient. Much of the published RWE originates from specific regional cohorts, which means subgroup findings are uncertain for other global populations.

Long-Term Data and Follow-Up

The majority of pivotal clinical trials are characterized by an intermediate follow-up duration, commonly based on observation periods of 24 weeks (six months). This follow-up period is typical for the primary analysis of clinical trials, but it means there is limited information for long-term outcomes. While observational studies have tracked patients over extended periods, the full effect on health outcomes over many years is not fully established. Evidence highlights what is known—the intermediate-term changes in glycemic biomarkers—and what is still uncertain regarding long-term durability.

Uncertainty and Research Gaps

Several important areas remain uncertain. Comparative evidence is lacking for a direct comparison between the FDC tablet and the practice of taking the two component drugs separately at the same time. Furthermore, research predominantly provides insight based on biomarker changes rather than comprehensive data on clinical events (such as hospitalization rates). These study results reflect the specific conditions under which they were conducted, and research is ongoing.

Common questions about Endial Met (FAQ)

Q: Can Endial Met be used for something other than its approved main purpose?

Official regulatory documents strictly define the approved purpose of this medication. It is indicated only for the management of Type 2 Diabetes Mellitus in adults. Regulatory documents do not contain information regarding use for conditions other than the approved indication.

Q: How quickly does Endial Met typically start to work?

While the medication begins to act after administration, the maximum effect on blood sugar markers is typically seen gradually over time. Clinical trials that establish the drug's effectiveness often monitor changes in key blood sugar markers, like HbA1c, over an intermediate follow-up period, such as 24 weeks. The dosing of this medication is highly individualized, requiring gradual adjustments.

Q: Does Endial Met cause weight gain or weight loss?

Clinical studies for this combination medication monitor changes in body weight as an outcome. The two components have different actions: the Metformin component is generally associated with modest weight loss, while the Glimepiride component can be associated with the potential for weight gain. The net effect on body weight in clinical trials is variable, reflecting the different actions of its two components.

Q: Why is Endial Met generally associated with a specific type of diet or lifestyle change?

Regulatory documents explicitly state that this medication is indicated for use as an adjunct to diet and exercise to help improve blood sugar control. This is consistent with the standard management of Type 2 Diabetes. Following appropriate dietary and lifestyle measures is described in counseling instructions as a factor that may help reduce the risk of low blood sugar ( hypoglycemia).

Q: Does Endial Met affect the ability to drive or operate machinery?

Official information warns that this medication can cause low blood sugar ( hypoglycemia), which may lead to symptoms like dizziness or confusion that could decrease alertness. Regulatory documents note that caution is required if performing skilled tasks, due to the potential for these effects.

Q: Is it normal to feel dizzy when first starting treatment with Endial Met?

Dizziness is a possible symptom of low blood sugar, or hypoglycemia, which is a commonly reported side effect, particularly from the glimepiride component. The risk of side effects, including hypoglycemia, is officially noted as more frequently observed during the initial phase of treatment.

Q: What are the ingredients in Endial Met besides the main active component?

Official product information documents the full composition of the tablet, not just the active ingredients (Glimepiride and Metformin). This complete list includes non-active components, known as excipients, which may include substances like lactose monohydrate, magnesium stearate, and microcrystalline cellulose.

Q: Is a headache a known side effect of taking Endial Met?

Yes, official regulatory labeling indicates that headache is an officially listed and commonly reported adverse reaction. This finding is based on data collected during clinical trials for the combination medication.

Q: Is it common to feel tired when taking Endial Met?

Yes, official documents mention that tiredness or general weakness (asthenia) is a reported adverse reaction. Furthermore, profound weakness or tiredness may be a potential symptom of the rare but serious metabolic condition known as lactic acidosis.

Q: Can Endial Met interact with common over-the-counter pain relievers?

Official drug interaction documents warn about co-administration with certain over-the-counter medications, particularly the class of drugs known as salicylates (which includes aspirin). These substances are noted to potentially alter the medication's blood sugar-lowering effect.

Q: Is Endial Met considered a first-line treatment option?

Official indications define this medication's place in the treatment plan. It is used to improve blood sugar control in adults with Type 2 diabetes whose condition is inadequately controlled when using other treatments alone. This suggests its intended use follows other therapies that have proven insufficient.

Q: Does Endial Met have different strengths available?

Yes, official product information confirms that the medication is available in specific fixed-dose combinations. These typically include combinations of the two active ingredients, Glimepiride and Metformin, in various defined strengths.

Q: How does Endial Met differ from a medicine that only contains Metformin?

Endial Met is a combination medicine that includes both Metformin and Glimepiride. The key difference is the Glimepiride component, which acts to stimulate the pancreas to release more insulin—an action not provided by Metformin alone.

Q: What should be done if someone accidentally takes too much Endial Met?

Official information warns that taking an overdose of this medication can lead to severe low blood sugar ( hypoglycemia) or the rare, serious metabolic complication known as lactic acidosis. Official information states that immediate medical attention is necessary in the event of an overdose.

Q: Does Endial Met interact with herbal supplements like St. John's Wort?

Regulatory documents warn that the Glimepiride component's exposure can be altered by drugs that affect the CYP2C9 enzyme. Supplements like St. John's Wort are known to interact with this enzyme, and this interaction may affect the concentration of Glimepiride in the body.

How to Store and Dispose of Endial Met?

The storage and disposal of Endial Met (Glimepiride and Metformin Hydrochloride tablets) must align with official regulatory requirements to ensure product stability and safety.

Storage Requirements

Endial Met must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The product should be kept in its original container to protect it from moisture. It must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Endial Met should be disposed of by returning it to an official drug take-back program. If a take-back program is not available, the tablets must be mixed with an unappealing substance, sealed in a container, and discarded with household trash. The medication must not be flushed down the toilet or poured into a drain.